Background: Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide. Although chemotherapy is the primary means in colorectal cancer treatment, it is burdenerd by adverse drug effects. Drug-resistance is one of the most important challenges for chemotherapy and epithelial-mesenchymal transition (EMT) plays critical role in the development of drug resistance. Aims: The aim of this study was to investigate the mechanisms underlying the effect of astragaloside IV (AS-IV) on miR-134 expression, EMT and chemotherapeutic sensitivity in CRC. Methods: Cell proliferation, transfection assay, western blot, real-time PCR, cell migration and invasion assay and luciferase reporter assay were used to detect the effects of AS-IV on CRC. Results: AS-IV significantly inhibited CRC cell migration and invasion by inducing miR-134 expression. Moreover, AS-IV and miR-134 increased the sensitivity of CRC tumors to oxaliplatin (OXA) chemotherapy. cAMP responsive elementbinding protein 1 (CREB1), which was required for CRC cells migration, invasion and drug sensitivity, was significantly down-regulated by AS-IV. Conclusions: Our results indicated that AS-IV inhibited CRC EMT by inducing miR-134 expression which significantly down-regulated the CREB1 signaling pathway, and therefore increased the sensitivity to chemotherapy. Our findings provided new insight into the mechanisms of chemotherapy-resistant CRC, and may open new therapeutic options in the treatment of this devastating disease.
Introduction
Colorectal cancer (CRC), the second most common types of non-skin cancer, is one of the leading causes of cancer deaths in both men and women [1, 2] . As the first-line treatment for CRC, especially in metastatic CRC, chemotherapy can effectively improve the clinical symptoms, reduce the volume of the tumors, prevent tumor metastasis and prolong survival time for CRC patients [3, 4] . However, most patients ultimately develop drug resistance after chemotherapy treatment. Previous studies suggested that epithelial-mesenchymal transition (EMT), one of the main characteristics of drug resistance, played a key role in the initiation of metastasis for cancer progression [5] [6] [7] . Hence, understanding the mechanisms underlining the effect of EMT signaling induced by chemotherapy on CRC is necessary for the development of novel therapeutic strategies to prevent or overcome chemotherapy related drug resistance.
The small non-coding RNAs (miRNAs) are key molecules in controlling posttranscriptional gene expression [8] . Abnormal high expression of miRNAs have been showed in various cancers, including gastric cancer, esophageal cancer and CRC [9, 10] . Targeting miRNAs involved in EMT signaling was studied as an emerging method to prevent drug resistance [11] . Recent studies showed that various miRNAs participated in the process of inhibiting EMT signaling [12] [13] [14] [15] . MiR-134, one of the miRNAs family members, has been identified as a suppressor of EMT [16] [17] [18] . However, the mechanism of chemotherapy induced EMT by miR-134 in CRC is still obscure.
Traditional Chinese medicine (TCM) has been studied and used in different cancer treatment [19] [20] [21] . Astragaloside IV (AS-IV), a TCM, is widely used to treat esophageal cancer and breast cancer [22, 23] . Li and co-workers recently demonstrated that AS-IV could inhibit migration and invasion in esophageal cancer cells by increasing connexin expression and enhancing gap junction function [22] . In this study, we found that AS-IV significantly reduced EMT relevant protein expressions and increased the sensitivity to chemotherapeutic agents via promoting miR-134 expression in CRC. In addition, the results also revealed that CREB1 was a functional target of AS-IV in CRC. The results provided significant insights in the prevention of chemotherapy-resistance in CRC.
Materials and Methods
Reagents AS-IV, EZ-Cytox, miR-134 inhibitor and Cell proliferation assay kit were purchased from Sigma-Aldrich (St. Louis, MO, USA). Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS) and penicillin were purchased from Hyclone Laboratories (Logan, UT, USA). The Annexin V-FITC apoptosis detection kit was purchased from BD Biosciences (Franklin Lakes, NJ, USA). Anti-E-cadherin, anti-N-cadherin, anti-Snail, anti-vimentin, anti-CREB1 and anti-GAPDH antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Cell culture SW-480 cells were cultured and maintained in DMEM supplemented with 10% FBS and antibiotics (500 μg/mL penicillin and 500 μg/mL streptomycin) at 37 °C in a humidified atmosphere with 5% CO 2 .
To identified the effect of AS-IV on proliferation and EMT. SW-480 cells transfected with/without miR-134 were treated with serial of drug concentrations (0, 5, 10, 25, 50 μg/mL) of AS-IV for 24 hours (h) and 48 h.
Cell proliferation assay
Cell proliferation was evaluated by the CCK-8 assay using the EZ-Cytox Cell proliferation assay kit according to the manufacturer's instruction (St. Louis, MO, USA). Briefly, SW-480 cells were plated in 96-well plates at a density of 1 × 10 4 cells/well overnight and then treated with different concentrations of AS-IV (0, 5, 10, 25, and 50 μg/mL) for 24 h or 48 h, respectively. Next, the reagent from the EZ-Cytox kit was added to each well for 30 min; the plates were then placed on a shaker for 30 s and the absorbance was measured at 450 nm using a microplate reader (model 680; Bio-Rad, Hercules, CA, USA). Transfection experiments miR-134 mimics and negative control (NC) were purchased from GenePharma (China). Small interfering RNA against CREB1 (si-CREB1) and negative control (si-NC) were synthesized by RiboBio (China). The sequences of the si-CREB1 were: sense 5'-AUUGUUAGCCAGCUGUAUUG-3', antisense 5'-CAAUACAGCUGGCUAACAAU-3'. Transfection was performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Transfection efficiency was monitored by Western blot.
Western blot analysis
Cell lysates were subjected to western blot analysis, according to standard protocols. Membranes were incubated with the corresponding antibodies or GAPDH antibodies overnight at 4 °C. The membranes were incubated with secondary antibody conjugated with horseradish peroxidase for 1 h at room temperature. The intensity of protein bands was quantified by densitometry and analyzed using Image J software (NIH).
RNA and miRNA extraction and real-time polymerase chain reaction miRNA from SW-480 cells was extracted according to the manufacturer's instructions using a miRNA Kit (Ambion, Carlsbad, MA), and the expression levels of miRNA-134 were detected by the Power SYBR Green PCR Master Mix (Ambion, Carlsbad, MA), using U6 small nuclear RNA as an internal control. The relative expression of target genes was determined using the 2 −ΔΔCt method.
Assessment of chemotherapy sensitivity and apoptosis
SW-480 cells were trasfected with miR-134 mimics (50 nM), siCREB1 (20 nM) or treated with AS-IV (10 μg/ml) following treatment with oxaliplatin (OXA, range, 0-2000 mg/mL). Cell viability was assessed by CCK-8 assay. For the apoptosis analysis, CRC cells were treated with oxaliplatin (200 mg/mL) for 48 h. The cells were then harvested and subjected to apoptosis analysis using an Annexin V-FITC and propidium iodide labeling kit (Invitrogen).
Cell migration and invasion assay
The migration ability of SW-480 cells was tested using a Transwell Boyden Chamber (8-mm pore size, BD Biosciences), as previously described [24] . For the cell invasion assay, the polycarbonate membranes of the upper compartment of the chambers were pre-coated with a matrix gel (BD Biosciences, Franklin Lakes, NJ, USA).
Luciferase reporter assay SW-480 cells were cultured in 96-well plates and cotransfected with 50 nmol/L of miR-134 mimic or NC, 50 ng of luciferase reporter, and 10 ng of pRL-CMV Renilla luciferase reporter using Lipofectamine 3000. The luciferase activities were assessed using a luciferase assay kit (Promega) at 48h after transfection.
Statistical analysis
All data were presented as the mean ± SD, data visualization was performed using the GraphPad Prism 6.0 software. Statistical comparison between two groups was performed using Student's t tests; Statistical comparison among three or more groups, one-way analysis of variance (ANOVA) followed by a Tukey's multiple comparisons test was used. A value of P<0.05 was considered statistically significant.
Results

Effect of AS-IV on the proliferation and EMT signaling in SW-480 cell
To analyze the effects of AS-IV on the proliferation in human CRC cells, SW-480 cells were treated with AS-IV under different concentrations for 24 h or 48 h. The proliferation assay results showed that AS-IV significantly suppressed SW-480 cells proliferation in a dose and time-dependent manner (Fig. 1A) . To further investigate whether AS-IV influenced EMT signaling, several key regulators in this pathway were analyzed at the protein level. As shown in Fig. 1B and 1C , AS-IV increased the E-cadherin protein level and decreased the protein levels of N-cadherin, Snail and Vimentin in SW-480 cells with time and dose dependence.
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Interestingly, we observed that miR-134 expression level was significantly upregulated upon the treatment of AS-IV (Fig. 1D) . We also found the miR-134 expression was suppressed by a miR-134 specific inhibitor. miR-134 expression level was increased after transfection with miR-134 in SW-480 cells, while significantly decreased after treatment with the miR-134 inhibitor (Fig. 1D) . Moreover, transwell assay was carried out to evaluate the inhibitory activity of AS-IV on the EMT signaling. The result of transwell assay suggested that both of AS-IV and miR-134 significantly inhibited the migration and invasion capacities of SW-480 cells, which reversed by the miR-134 inhibitor treatment ( Fig. 1E and F) . cAMP responsive element binding protein 1 (CREB1) is a proto-oncogene to regulate diverse cellular responses, including proliferation, survival and differentiation, which contributed to the carcinogenesis and cancer progression. Previous studies have suggested that CREB1 played an important role in mediating EMT signaling. Subsequently, we explored the effects of AS-IV or miR-134 on the regulation of EMT signaling in SW-480 cells. Western blotting assay indicated that miR-134 and AS-IV significantly decreased the expression level of CREB1, whereas the miR-134 inhibitor obviously promoted the expression level of CREB1 (Fig. 1G ). In addition, the results also showed that miR-134 and AS-IV increased the miR-134 expression (Fig. 1H) . 
AS-IV treatment enhanced chemotherapeutic sensitivity in SW-480 cells.
To further investigate the EMT inhibitory ability of AS-IV, a cytotoxic assay (CCK-8 assay) was used to evaluate the effect of AS-IV on chemotherapeutic sensitivity of CRC. Survival rate of SW-480 cells in the presence of AS-IV was significantly lower than that of the control group ( Fig. 2A and B) . The result suggested that both of AS-IV and miR-134 significantly enhanced the sensitivity of tumor cells to chemotherapeutic agent OXA. In flow cytometry analysis, a major population of miR-134-treated cells was observed in the Q4-LR quarter, indicated that miR-134 and AS-IV could intensify the early apoptosis induced by OXA in SW-480 cells (Fig. 2C and D) .
CREB1 was an important functional target of miR-134 in SW-480 cells
To validate the relationship between CREB1 and miR-134 in SW-480 cells, the potential base pairing between miR-134 and the 3'-UTR of CREB1 was evaluated. As expected, CREB1 was predicted as one of the targets determined by TargetScan 6.2 (Fig. 3A) . The luciferase reporter assay indicated that miR-134 significantly inhibited the luciferase activity of wildtype (Wt) 3'UTR of the CREB1 gene in SW-480 cells (Fig. 3B) . In contrast, CREB1 expression had not been suppressed by miR-134 when mutations were introduced into the 3'-UTR of CREB1 (Fig. 3B) . Western blot results further verified the effect of miR-134 on the expression level of CREB1 in SW-480 cells (Fig. 3C and D) . These results showed that the accumulated miR-134 resulted in a decrease both in mRNA and protein expression levels of CREB1 in SW-480 cells. Taken together, we found a significantly inverse correlation between CREB1 level and miR-134 expression in CRC cells.
Knockdown of CREB1 inhibited CRC cell proliferation, migration and increased drug sensitivity in vitro
In order to further confirm the role of CREB1 in CRC, we knocked down CREB1 in SW-480 cells by transfection with siRNA (si-CREB1). CREB1 level was significantly reduced after knockdown of CREB1 in SW-480 cells (Fig. 4A) . Moreover, si-CREB1 treatment effectively prevented migration and invasion of SW-480 cells (Fig. 4B ). In addition, the effect of OXA on 
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Cellular Physiology and Biochemistry suppressor and increased drug sensitivity in various cancers [29, 30] . Overexpression or downregulation of miR-134 expression by miR-134 mimics or miR-134 inhibitors in Small Cell Lung Cancer (SCLC) cell lines were significantly correlated with inhibition of cell growth and induction of apoptotic cell death [31] . Chang et al. found that miR-134 could be validated as a marker for diagnosis in oral squamous cell carcinoma [32] . Yu et al. reported that the level of miR-134 expression was associated with invasion ability and EMT phenotype in nonsmall cell lung cancer cells. In our study, AS-IV significantly inhibited the expression of EMT related protein expression levels. Interestingly, AS-IV and miR-134 were found to inhibit cell invasion and migration in human CRC SW-480 cells. In addition, the sensitivity to OXA was significantly increased by AS-IV or miR-134 in SW-480 cells. The results indicated that miR-134 could suppress the invasion and migration and induce apoptosis in SW-480 cell. CREB1, a crucial transcription factor, has been verified as a target of several miRNAs, which involved in the miRNA mediated EMT signaling, proliferation and drug resistance in cancer cells [33] . Li et al. reported that miR-200b targeted the CREB1, which showed antitumor activity in human malignant glioma [34] . Zheng et al. discovered CREB1 was the downstream target gene of miR-433 involving the EMT signaling [35] . Qu et al. showed that miR-150 significantly enhanced EMT signaling by regulating the CREB1 expression in CRC cells [36] . He et al. demonstrated that miR-27b-3p directly targeted and inhibited the expression of CREB1, which played a key role in the resistance to tamoxifen in breast cancer cells [37] . Our results showed that down-regulation of CREB1 inhibited cell migration, invasion and induced cell apoptosis. The results also demonstrated that CREB1 was a direct target of miR-134 and its expression was reciprocally correlated with the miR-134 level, which were in accordance with results from previous studies [38, 39] .
Conclusion
Our results showed that knockdown of CREB1 could inhibit the invasion and migration and induce apoptosis in SW-480 cells. In addition, the results also demonstrated CREB1 was a target of miR-134 determined by luciferase reporter assay. Our study also indicated miR-134 significantly increased cell apoptosis via downregulation of CREB1 expression, which suggested miR-134 could increase the sensitivity to chemotherapeutic drug in SW-480 cells. Above all, our findings showed that miR-134 induced by AS-IV significantly suppressed EMT signaling and enhanced chemotherapeutic sensitivity via inhibiting CREB1 expression in SW-480 cells. We anticipated that these findings could be utilized as a promising new therapeutic strategy for the treatment of colorectal cancer.
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